Big foreign makers face heat from generics

Published: 2004-09-07 07:00:00

Updated: 2004-09-07 07:00:00

Some of foreign-invested pharmaceutical firms, such as Pfizer Korea and Handok Pharm, face an aggressive assault as local firms look to steal market share by launching a number of amlodipine and glimepiride generics to jump-start sluggish sales in the midst of protracted business slump.

Pfizer...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK